Although CAR-T therapy shows good therapeutic outcomes and great potential for curing blood cancers, there still are technical limitations in adopting it in the treatment of solid cancers. The absence of cancer-specific antigen on solid cancer cells is likely to lead to toxicity to normal cells, immune evasion by cancer cells limits the efficacy, and clonal heterogeneity of cancer cells causes disease relapse.

InnoBation Bio’s InteliCAR-T therapy boldly challenges the current limitations of traditional CAR-T therapy and aims for curing solid cancers. InteliCAR-T cell holding two different antigen receptors grants enhanced efficacy and secures safety by selectively targeting cancer cells.